Designing A Cancer-Killing Virus

October 29, 2007 – 2:20 pm | posted in Cancer / Oncology

One new way to treat individuals with cancer that is being developed is the use of viruses that infect and kill cancer cells while leaving normal cells unharmed. These viruses are known as virotherapeutics. In a new study, David Kirn and colleagues at Jennerex Biotherapeutics, San Francisco, have described the development of a new virotherapuetic with antitumor effects in both mice and rabbits.

After selecting a highly potent strain of poxvirus that was able to traffic to tumors when administered intravenously to mice the authors engineered the virus such that it would target only specific cancer cells — those with increased expression of a protein known as E2F and/or activation of signaling downstream of a protein known as EGFR. Further engineering to enable the virus to produce the soluble factor GM-CSF was designed to enhance the induction of anti-tumor immune responses. In addition to its antitumor effects in mice and rabbits, the virotherapeutic showed high selectivity for cancer cells in tumor-bearing rabbits and in human tissue samples, leading the authors to suggest that this virotherapeutic should be tested in clinical trials for the treatment of cancer.

Also Read

  • Clues To Next Pandemic Found In Structure Of Influenza B Virus Protein
  • Avian Flu Virus Unlikely To Spread Through Wastewater And Drinking Water Treatment Systems, Cornell Researchers Find
  • With BYU Partner, FSU’s Magnet Lab Researchers Deciphering Flu Virus
  • News From The Journal Of The National Cancer Institute
  • Ebola Virus Killing Off Gorilla Populations In Africa
  • Jefferson Researchers Boost Immune ‘killer Cells,’ Increase Antibody Effectiveness Against Cancer
  • Virtual Study Of Epstein-Barr
  • Study Examines How HIV Progresses To AIDS
  • Genes That Allow Brain Cancer-Causing Stem Cells To Resist Treatment Identified
  • Human Papilloma Virus (HPV) Vaccines May Decrease Chances Of Oral Cancer
  • You must be logged in to post a comment.